|
PRESS RELEASE Countering the next phase of antivaccine activism
![Image Caption: Fig 1. Comparing the risk of 10,000 children acquiring measles (left) versus receiving the measles-mumps-rubella (MMR) vaccine. A new original figure modified from [9]. Artwork by Fahim Akbar.
Image Credit: Hotez, 2025, PLOS Global Public Health, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)](../images/journal-pgph_0004020.g001.jpg "Image Caption: Fig 1. Comparing the risk of 10,000 children acquiring measles (left) versus receiving the measles-mumps-rubella (MMR) vaccine. A new original figure modified from [9]. Artwork by Fahim Akbar. Image Credit: Hotez, 2025, PLOS Global Public Health, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)")
January 8, 2025
In a recent essay, pediatrician-scientist Peter Hotez proposes a focus on local data, improved benefit-risk communications, actively countering health disinformation, and state-level action to address antivaccine sentiment in the U.S.
Anti-vaccine sentiment isn’t going away any time soon. In a new opinion article published January 8 in the open-access journal PLOS Global Public Health, Prof. Peter Hotez from Baylor College of Medicine, outlines key actions to stem the momentum of anti-vaccine advocates in the U.S. over the next five years.
Anti-vaccine activities in the U.S. transformed to become a politically charged movement during the COVID-19 pandemic as calls for health freedom characterized partisan political activism. In his recent opinion piece, Hotez argues that, as COVID-19 hospitalizations and deaths decline, anti-vaccine attitudes have not decreased but merely shifted—toward childhood vaccinations. Vaccine hesitancy among parents for childhood vaccines is likewise politically divided, and the country has seen re-emergence of multiple preventable childhood illnesses, including whooping cough and measles. Recently, even polio has been detected in wastewater sampling.
Hotez warns that without urgent action, these isolated outbreaks of childhood illnesses may become regular breakthrough epidemics. He outlines short-term steps for researchers, policymakers, and communicators, including updating local-level data to identify pockets of vaccine hesitancy and focusing on state-level actions to maintain vaccination coverage. In addition, he calls for broader efforts to accurately communicate the risks of preventable illnesses and combat disinformation in real time. Instead of relying on the efforts of individual scientists to correct false information, Hotez proposes that a government-established credible website to debunk vaccine myths in easy-to-understand language.
The authors add: “Our vaccine ecosystem is fragile and the troubling rise in cases of measles, pertussis, and other illnesses requires enhanced measures to counter antivaccine activism. Critical steps include mapping of hotspot counties with significant vaccine exemptions, improved benefit-risk communication graphics, exposing disinformation, and implementing sound vaccine policies in state legislatures.”
PLOS Global Public Health:
It won’t end with COVID: Countering the next phase of American antivaccine activism 2025–29
Contact: Peter Hotez, hotez@bcm.edu; Douglas Soriano, Douglas.SorianoOsejo@bcm.edu; General media inquiries, homa.shalchi@bcm.edu, press@tchteam.com, kfcarvil@texaschildrens.org
Image Caption: Fig 1. Comparing the risk of 10,000 children acquiring measles (left) versus receiving the measles-mumps-rubella (MMR) vaccine. A new original figure modified from [9]. Artwork by Fahim Akbar.
Image Credit: Hotez, 2025, PLOS Global Public Health, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
High-Resolution Image Link: https://plos.io/3C1e5sZ
Citation: Hotez P (2025) It won’t end with COVID: Countering the next phase of American antivaccine activism 2025–29. PLOS Glob Public Health 5(1): e0004020. https://doi.org/10.1371/journal.pgph.0004020
Author Countries: United States
Funding: The author received no specific funding for this work.
Competing Interests: Peter Hotez is a co-inventor on non-revenue generating patents for neglected tropical diseases owned by Baylor College of Medicine (BCM). He is also a co-inventor of a COVID-19 recombinant protein vaccine technology owned by BCM that was recently licensed by Baylor Ventures non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. These include Biological E (India), BioFarma (Indonesia), Incepta (Bangladesh) and ImmunityBio (United States with partnerships is the African Continent including Botswana and South Africa). The co-inventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries and that result in a commercial license, a share of any royalty income. Any such distribution will be undertaken in accordance with BCM policy.
About PLOS Global Public Health
PLOS Global Public Health is a global forum for public health research that reaches across disciplines and regional boundaries to address some of the biggest health challenges andinequities facing our society today. For more information, visit https://journals.plos.org/globalpublichealth, and follow @PLOSGPH on Twitter.
Media and Copyright Information
For information about PLOS Global Public Health relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit https://plos.org/press-and-media/.
PLOS Journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited.
About the Public Library of Science
PLOS is a nonprofit, Open Access publisher empowering researchers to accelerate progress in science and medicine by leading a transformation in research communication. We’ve been breaking boundaries since our founding in 2001. PLOS journals propelled the movement for OA alternatives to subscription journals. We established the first multi-disciplinary publication inclusive of all excellent research regardless of novelty or impact, and demonstrated the importance of open data availability. As Open Science advances, we continue to experiment to provide more opportunities, choice, and context for readers and researchers. For more information, visit http://www.plos.org.
Disclaimer
This press release refers to upcoming articles in PLOS Global Public Health. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
Source: PLOS Global Public Health
https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0004020%20
"Reproduced with permission - PLOS Global Public Health"
PLOS Global Public Health
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
